ℹ Important Notice: Pharma products are sold and shipped exclusively to registered medical professionals at verified medical premises.
Non-approved buyers:
Complete our Online POM Form, and we will notify you once your account is Pharma approved.
Powder and solvent for suspension for injection, sustained release formulation. Powder: White to off-white powder. Solvent: Clear solution.
Therapeutic indications
• Treatment of patients with locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration.
• Treatment of metastatic prostate cancer.
• As adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.
• As neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.
• As adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression.
• Treatment of central precocious puberty (CPP) in children 2 years and older with an onset of CPP before 8 years in girls and 10 years in boys).
Features
Nature and contents of container
• 6 mL septum vial with bromobutyl stopper and aluminium flip-off cap.
• Ampoule containing 2 mL of sterile solvent for suspension.
Special precautions for storage
• Do not store above 25°C. Keep the container in the outer carton. The reconstituted suspension for injection should be used immediately.
Shelf life
• The product should be used immediately after reconstitution.
Patient Information Leaflet
https://www.medicines.org.uk/emc/files/pil.5906.pdf
| Presentation | Vial |
| Presentation | Vial |
| Pack size | 1 |
| Presentation | Vial |
